Physician profile
Marc E Johnson
NPI 1730475815
$5,737.86
in general payments reported to CMS, 2019-2025
30 companies · $532 in 2025
The $532 reported for 2025 was more than what 77% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,661 · 2020: $1,391 · 2021: $172 · 2022: $613 · 2023: $634 · 2024: $734 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,900.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,932.98 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Astrazeneca Pharmaceuticals LP | $796.00 | 2019-2020 | |
| Gilead Sciences, INC. | $553.05 | 2019-2023 | Biktarvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.68 | 2019-2020 | |
| Glaxosmithkline, LLC. | $307.07 | 2019-2020 | |
| Novo Nordisk INC | $295.94 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $262.28 | 2019-2025 | Pifeltro, Delstrigo |
| Janssen Biotech, INC. | $156.88 | 2020-2021 | |
| Theratechnologies INC. | $143.17 | 2023-2024 | Egrifta Sv, Trogarzo, Egrifta |
| Insmed, INC. | $111.18 | 2023 | Arikayce |
| Insulet Corporation | $108.76 | 2025 | Omnipod |
| Dexcom, INC. | $106.77 | 2023 | Dexcom G7 Gss (161) |
| Janssen Pharmaceuticals, INC | $93.34 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $90.41 | 2019-2020 | |
| Abbvie INC. | $49.97 | 2021-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Products, LP | $49.95 | 2021 | |
| Hikma Pharmaceuticals USA | $42.19 | 2019-2020 | |
| Lilly USA, LLC | $39.87 | 2019-2020 | |
| Shire North American Group INC | $37.45 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.58 | 2020 | |
| Astellas Pharma US INC | $31.52 | 2019 | |
| Genentech USA, INC. | $26.22 | 2019 | |
| Pfizer INC. | $25.21 | 2019-2020 | |
| Amgen INC. | $24.91 | 2019 | |
| Allergan, INC. | $24.26 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.34 | 2020 | |
| Inari Medical, INC. | $15.15 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Mylan Specialty L.P. | $13.50 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.93 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.